Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
As a novel radiotracer targeting fibroblast activation protein (FAP), 68Ga-DOTA-NI-FAPI04 is a novel agent incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a FAP-targeting. In this study, we observed the diagnostic performance of 68Ga-DOTA-NI-FAPI04 PET/CT in patients with different types of cancer, and compared its imaging results with those of 68Ga-FAPI or 18F-FDG PET/CT.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-04-01
Completion Date
2025-12-31
Last Updated
2024-06-12
Healthy Volunteers
No
Conditions
Interventions
68Ga-DOTA-NI-FAPI04
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
68Ga-FAPI/18F-FDG
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Locations (1)
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China